Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: REVLIMID

Summary for Tradename: REVLIMID

Suppliers: see list1
patent expirations by year for

Pharmacology for Tradename: REVLIMID

Clinical Trials for: REVLIMID

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Status: Recruiting Condition: Multiple Myeloma

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Status: Active, not recruiting Condition: Follicular Lymphoma; Marginal Zone B-Cell Lymphoma; MALT Lymphoma; Lymphoma of Mucosa-Associated Lymphoid Tissue; Lymphoma, Small Lymphocytic; Waldenstrom Macroglobulinemia; Mantle-Cell Lymphoma

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Status: Completed Condition: Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)

Dasatinib in Combination With Revlimid (and Dexamethasone)
Status: Completed Condition: Multiple Myeloma

A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age
Status: Active, not recruiting Condition: Acute Myeloid Leukemia; Acute Myelogenous Leukemia

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Status: Recruiting Condition: Lymphoma, Non-Hodgkin

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Status: Completed Condition: Cutaneous Lupus Erythematosus (CLE)

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Status: Active, not recruiting Condition: HIV-1 Infection

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Status: Active, not recruiting Condition: Multiple Myeloma

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Status: Recruiting Condition: Myeloma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
CAPSULE;ORAL021880Dec 21, 2011RXNo<disabled><disabled>
CAPSULE;ORAL021880Dec 21, 2011RXNo<disabled><disabled>
CAPSULE;ORAL021880Dec 21, 2011RXNo5,635,517<disabled>Y<disabled>
CAPSULE;ORAL021880Dec 21, 2011RXNo6,045,501<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: REVLIMID

Drugname Dosage Strength RLD Submissiondate
lenalidomideCapsules5 mg, 10 mg and 15 mgRevlimid8/30/2010
lenalidomideCapsules25 mgRevlimid7/12/2010

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology